Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Company Deals

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Fineline Cube May 13, 2026
Company Deals

Cellular Intelligence Acquires Global Rights to Novo Nordisk’s Parkinson’s Cell Therapy Program, Plans AI-Driven Acceleration

Fineline Cube May 13, 2026
Company Deals

Boehringer Ingelheim Secures Global Rights to Immunitas’ First-in-Class Antibody Program for Chronic Inflammatory Diseases in €407.5M Deal

Fineline Cube May 13, 2026
Policy / Regulatory

Hong Kong to Launch FDA-Style Medical Products Regulation Center by Year-End, Creating Gateway for Chinese Innovative Drugs

Fineline Cube May 13, 2026
Company Drug

Eli Lilly Reports Long-Term Weight Loss Maintenance with Foundayo and Lower-Dose Zepbound in Phase 3 Trials

Fineline Cube May 13, 2026
Company Drug

Servier’s B7-H4 ADC Emiltatug Ledadotin Receives FDA Breakthrough Therapy Designation for Advanced Adenoid Cystic Carcinoma

Fineline Cube May 13, 2026
Company Deals

China’s HiRO Expands US Presence with Acquisition of New Jersey-Based DeltaMed Solutions

Fineline Cube Jul 4, 2024

Harvest Integrated Research Organization (HiRO), a China-based ’boutique’ Contract Research Organization (CRO), has expanded its...

Company Drug

LG Chem and Yifan Pharmaceutical Launch Hyruan ONE for Knee Osteoarthritis in China

Fineline Cube Jul 4, 2024

LG Chem, a leading chemical company based in South Korea, and Yifan Pharmaceutical Co., Ltd...

Company Drug

AstraZeneca’s Voydeya Receives South Korean Approval for PNH Treatment

Fineline Cube Jul 4, 2024

AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical giant, has reportedly secured market approval in South...

Company Deals

Chengdu-Based Vaccine Specialist Maxvax Biotechnology Raises USD 41.3 Million in Latest Funding Round

Fineline Cube Jul 3, 2024

Maxvax Biotechnology, a leading vaccine-focused biotech company headquartered in Chengdu, has successfully closed its Series...

Company Drug

Astellas Pharma’s Xtandi Secures Third Market Approval in China for Prostate Cancer Treatment

Fineline Cube Jul 3, 2024

Astellas Pharma Inc. (TYO: 4503), a leading Japanese pharmaceutical company, has announced that it has...

Company

Novartis Launches Construction of First Radioligand Manufacturing Site in China

Fineline Cube Jul 3, 2024

Novartis AG (NYSE: NVS), the Swiss pharmaceutical giant, has initiated construction on its second manufacturing...

Company Drug

Eslicarbazepine Makes First Appearance in China at Sichuan University’s West China Lecheng Hospital

Fineline Cube Jul 3, 2024

Eslicarbazepine, a voltage-gated sodium channel blocker, co-developed by Bial-Portela, Eisai, and Sumitomo Pharma, was first...

Company Deals Medical Device

Jiangsu Vcare Pharma Partners with Geneseeq Technology to Develop Companion Diagnostic for NTRK Inhibitor

Fineline Cube Jul 3, 2024

Jiangsu Vcare PharmaTech Co., Ltd, a biopharmaceutical company based in China, has entered into a...

Company Drug

China’s Jiangsu Hengrui First to Market Generic Exparel in the US with FDA ANDA Approval

Fineline Cube Jul 3, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Drug

Shanghai Henlius Biotech Advances Serplulimab Phase III Trial for First-Line Metastatic Colorectal Cancer

Fineline Cube Jul 3, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696), a biopharmaceutical company based in China, has announced that...

Company Drug

MabPharm’s Biosimilar Infliximab CMAB807 Receives Market Approval in Peru

Fineline Cube Jul 3, 2024

MabPharm Ltd (HKG: 2181), a biosimilar specialist in monoclonal antibody (mAb) based in Taizhou, has...

Company Drug

Legend Biotech’s Carvykti Shows Significant Overall Survival Improvement in Phase III CARTITUDE-4 Study

Fineline Cube Jul 3, 2024

Legend Biotech Corporation (NASDAQ: LEGN) has announced positive results from the CARTITUDE-4 study, a global,...

Company Drug

Lilly’s Kisunla Poised to Shake Up Alzheimer’s Treatment Market with FDA Approval

Fineline Cube Jul 3, 2024

Eli Lilly & Co. (NYSE: LLY) has announced that the U.S. Food and Drug Administration...

Company Drug

Johnson & Johnson’s Talvey Gets Green Light in South Korea for Multiple Myeloma

Fineline Cube Jul 3, 2024

Johnson & Johnson (J&J; NYSE: JNJ) has announced that its subsidiary Janssen Korea has received...

Company Policy / Regulatory

LEK Consulting’s Survey Reveals Biosecure Act’s Impact on Life Sciences Companies

Fineline Cube Jul 3, 2024

LEK Consulting, a UK/US firm, has published the results of a global survey aimed at...

Company Deals

Bristol-Myers Squibb Ends Collaboration with Eisai on Farletuzumab Eteribulin

Fineline Cube Jul 2, 2024

Bristol-Myers Squibb (BMS; NYSE: BMY), a prominent US pharmaceutical company, has decided to terminate its...

Company Drug

Eli Lilly & Co. Strikes Deal for Radionetics’ GPCR-Targeted Radiopharmaceuticals

Fineline Cube Jul 2, 2024

Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company based in the US, has...

Company Drug

Boehringer Ingelheim Initiates Clinical Trial for Novel Anti-Obesity Drug

Fineline Cube Jul 2, 2024

Boehringer Ingelheim (BI), a German pharmaceutical company, has announced the commencement of clinical development for...

Company Drug

Tracon Pharmaceuticals Halts Development of Envafolimab After Clinical Trial Failure

Fineline Cube Jul 2, 2024

Tracon Pharmaceuticals (OTCMKTS: TCON), a US-based biopharmaceutical company, has decided to cease development of its...

Company Policy / Regulatory

US Forms ‘Bio-5’ Coalition with Global Powers to Reduce Reliance on Chinese APIs

Fineline Cube Jul 2, 2024

The White House announced last week a suite of new initiatives aimed at bolstering domestic...

Posts pagination

1 … 335 336 337 … 665

Recent updates

  • Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform
  • Eli Lilly Reports Long-Term Weight Loss Maintenance with Foundayo and Lower-Dose Zepbound in Phase 3 Trials
  • Legend Biotech Reports 56% Q1 Revenue Growth to $305M, Driven by Carvykti Sales Surge and J&J Milestone Payment
  • Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms
  • Sichuan Kelun-Biotech Receives NMPA Approval for ITGB6-Targeted ADC SKB105 in Advanced Solid Tumors Following Crescent Biopharma Licensing Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Company Drug

Eli Lilly Reports Long-Term Weight Loss Maintenance with Foundayo and Lower-Dose Zepbound in Phase 3 Trials

Company

Legend Biotech Reports 56% Q1 Revenue Growth to $305M, Driven by Carvykti Sales Surge and J&J Milestone Payment

Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.